Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25386564 | 0.97 | FFAR1 (0.34) | FFAR1CPT2TDP1 | |
| SCHEMBL7740664 | 0.97 | FFAR1 (0.34) | FFAR1CPT2TDP1 | |
| SCHEMBL10316755 | 0.97 | FFAR1 (0.34) | FFAR1CPT2TDP1 | |
| SCHEMBL25383840 | 0.97 | FFAR1 (0.34) | FFAR1CPT2TDP1 | |
| SCHEMBL1973892 | 0.92 | — | — | |
| SCHEMBL10316622 | 0.90 | FFAR1 (0.31) | FFAR1CPT2TDP1 | |
| SCHEMBL25384743 | 0.90 | TSHR (0.35) | — | |
| SCHEMBL25385601 | 0.87 | TSHR (0.40) | FFAR1CPT2TDP1 | |
| SCHEMBL25384437 | 0.87 | TSHR (0.40) | FFAR1CPT2TDP1 | |
| SCHEMBL25384575 | 0.87 | TSHR (0.40) | FFAR1CPT2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024018761-A1 | NEUTRAL LIPID AND LIPID NANOPARTICLE | 国立大学法人北海道大学 | 2024-01-25 | — | — | WO | disclosed |
| US-20240024252-A1 | LIPID NANOPARTICLE | NITTO DENKO CORPORATION (JP) | 2024-01-25 | — | — | US | disclosed |
| WO-2024018762-A1 | PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLE | 国立大学法人北海道大学 | 2024-01-25 | — | — | WO | disclosed |
| WO-2023188830-A1 | LIPID NANOPARTICLES | 国立大学法人北海道大学 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023191050-A1 | PHARMACEUTICAL COMPOSITION FOR DELIVERY TO CANCER, OR IMMUNOSTIMULATING COMPOSITION | 日東電工株式会社 | 2023-10-05 | — | — | WO | disclosed |
| EP-4223314-A1 | LIPID NANOPARTICLE | National University Corporation Hokkaido University (JP) | 2023-08-09 | — | — | EP | disclosed |
| CN-116367718-A | Lipid nanoparticles | 国立大学法人北海道大学 | 2023-06-30 | — | — | CN | disclosed |
| CN-102115437-B | Method for preparing gamma and delta unsaturated ketone | SHANGHAI HEGNO PHARMACEUTICAL DEV CO LTD | 2014-05-07 | — | — | CN | disclosed |
| EP-2520570-A1 | AMINOPYRIDINE COMPOUND | Ube Industries, Ltd. (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-10-11 | — | — | US | disclosed |
| CN-102666490-A | Aminopyridine compound | UBE INDUSTRIES | 2012-09-12 | — | — | CN | disclosed |
| US-20120226036-A1 | SUBSTITUTED CARBONYL COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| EP-2476678-A1 | SUBSTITUTED CARBONYL COMPOUNDS | Ube Industries, Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
| CN-102548985-A | Substituted carbonyl compounds | UBE INDUSTRIES | 2012-07-04 | — | — | CN | disclosed |
| CN-102115437-A | Method for preparing gamma and delta unsaturated ketone | SHANGHAI DESANO PHARMACEUTICALS HOLDING CO LTD | 2011-07-06 | — | — | CN | disclosed |
| EP-2013278-A1 | USE OF HEXAHYDROPHTHALIMIDE COMBINATIONS AS SOFTENER | BASF SE (DE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008006834-A2 | USE OF IMIDAZOLE COMPOUNDS AS PLASTICISERS | BASF SE (DE) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007122204-A1 | USE OF HEXAHYDROPHTHALIMIDE COMBINATIONS AS SOFTENER | BASF SE (DE) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024252-A1 | LIPID NANOPARTICLE | LIPC, ACOX1, ABCB4 | FFAR1 359/4885CPT2 427/4885TDP1 4237/4885 |
| US-20120226036-A1 | SUBSTITUTED CARBONYL COMPOUND | PTGER2, PTGER1, LTB4R2 | FFAR1 136/4885CPT2 113/4885TDP1 4750/4885 |
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | PTGIS, QDPR, PTGIR | FFAR1 2994/4885CPT2 1806/4885TDP1 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.